Chemistry

Still Stuck on Adhesion Issues, FDA Rejects DBV's Peanut Allergy Patch

1 month ago   |   By Xconomy

A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs to change its design and run another clinical trial testing the modified version if it wants the treatment reviewed again. DBV , which has its headquarters on the outskirts of Paris and US operations in New York and Summit, NJ, said Tuesday that the FDA letter noted in addition to generating more clinical data, the company must provide more specifications about chemistry, manufacturing, and controls, after reworking...
Read more ...

 


Search by Tags

   Chemistry      Clinical      Manufacturing      Europe blog main      Europe top stories      National      National blog main      National top stories      New York blog main      New York top stories      San Francisco blog main      Aimmune Therapeutics      Biotech      Complete response letter      DBV Technologies      FDA      Food allergy      Life Sciences      Palforzia      Peanut allergy      Viaskin  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Moderna CMO Talks COVID-19 Vaccine at Xcelerate Next Week

Moderna CMO Talks COVID-19 Vaccine at Xcelerate Next Week

The Xcelerate Keynote Series has added Moderna CMO Tal Zaks to the expert lineup of speakers set to present next Monday, Sept. 21. As you likely know, Moderna is one of the... Read more ...

Securely Emerging into the Quality Nebula

Securely Emerging into the Quality Nebula

Our Software Solutions Quality Document Management Success Written by: Candice Snine, Business Development Manager, PSC Biotech Quality Management in any industry is all about... Read more ...

BIO Chief: “Reckless” Executive Order on Drug Prices Threatens Innovation

BIO Chief: “Reckless” Executive Order on Drug Prices Threatens Innovation

The US is doing more in the COVID-19 space than anywhere in the world due to the strength of its innovative ecosystem, says Michelle McMurry-Heath, president & CEO of life... Read more ...

Dyne's Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

Dyne's Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

Dyne Therapeutics, a company developing genetic medicines for rare muscular disorders, has raised $233 million in an IPO that topped the preclinical-stage biotech's... Read more ...

Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline

Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline

When Seres Therapeutics reported positive late-stage data for its experimental microbiome treatment last month, scientists at Finch Therapeutics cheered the results from the... Read more ...

How SARS-CoV-2 Went from Single Cases to Overwhelming Continents

How SARS-CoV-2 Went from Single Cases to Overwhelming Continents

Early detection and intervention stanched the first known introductions of the SARS-CoV-2 virus into North America and Europe, validating the effectiveness of quick... Read more ...

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

An Arrowhead Pharmaceuticals drug for a rare liver disease now has early Phase 2 results and the data so far look good. Not only did the therapy reduce levels of a mutant... Read more ...

Easy and Affordable: Full-Length 16S HiFi Sequencing with PacBio Service...

Easy and Affordable: Full-Length 16S HiFi Sequencing with PacBio Service Providers

Analysis of 16S ribosomal RNA has been used for phylogenetics and identifying prokaryotes for decades. But just as scientists have had to refine the Linnaean taxonomy system... Read more ...

Chromatin regulates expression of small RNAs to help maintain transposon...

Eukaryotic genomes are partitioned into euchromatic and heterochromatic domains to regulate gene expression and other fundamental cellular processes. However, chromatin is... Read more ...

Removing reference bias and improving indel calling in ancient DNA data...

During the last decade, the analysis of ancient DNA sequence has become a powerful tool for the study of past human populations. However, the degraded nature of aDNA means that... Read more ...